Induced Trophoblast Stem Cells to Treat Pregnant Ladies with Placental Problems

Release Date: 19-Nov-2020

Recently, a collaboration has taken place between Duke-NUS Medical School and Monash University researchers for the overall development of the very first stem cell therapy against the placental complications that are observed by the pregnant ladies. It is estimated that induced pluripotent stem cells carries the capability to open up hundreds of novel avenues for global personalized cell therapies as well as regenerative medicine, overall safe drug testing and many others. 


Researchers have also concluded that induced trophoblast stem cells (iTSCs) are also capable of making placenta cells. All this have led to the conclusion that research could be performed to treat placenta complications and also measurement of drug toxicity to placenta cells occurring during pregnancy. It was found that induced pluripotent stem cells are not capable of developing placenta cells thus a novel research is important to translate the placental complications. The discovery of iTSCs will enable the researchers to model human placenta in vitro and provide a pathway that would enable hundreds of novel future therapies. The successful combination of applications of iTSCs and hundreds of computational tools will lead to an unexpected era of medical world, providing benefits to hundreds of patients.


Need custom market research solution? We can help you with that too.